However, we also observed several druggable pathway alterations in the tumor‐informed ctDNA group, such as ERBB2, MMR, and mTOR signaling (Figure 3J), suggesting that alternative strategies beyond immunotherapy might be considered. The gene discussed is MTOR; the disease is neoplasm.